The patient’s story began insidiously. For six months, the 79-year-old man experienced mild fatigue and generalized weakness that remained stable before worsening dramatically in the final month. He described episodes of his legs giving out, new-onset muscle cramping, dizziness, unintentional weight loss, night sweats, early satiety, anorexia, and nocturia. He denied any recent fever. Two weeks before admission, his primary care physician detected anemia and marked leukocytosis, an abnormally high white blood cell count, prompting referral for specialist evaluation. The patient had no significant past medical history, which made the laboratory findings that followed all the more alarming.

On admission, the numbers were staggering. His white blood cell count reached 292.74 × 10³/μL, roughly thirty times the upper limit of the normal range of 4 to 10 × 10³/μL. The differential count revealed a chaotic mixture: 42% neutrophils, 24% lymphocytes, 12% myelocytes, 8% band cells, 5% metamyelocytes, 1% promyelocytes, and 4% blasts, immature cells that should rarely appear in circulating blood. He was also profoundly anemic, with hemoglobin of 8.5 g/dL against a reference range of 12.3 to 15.3 g/dL, and an elevated red cell distribution width of 18.2% indicating marked variation in red cell size. His platelet count remained deceptively normal at 343 × 10³/μL. Lactate dehydrogenase, an enzyme released when cells die rapidly, was elevated at 890 U/L, signaling the intense cellular turnover characteristic of proliferative hematologic malignancies.

A peripheral blood smear provided the first major clue. The slide showed a full spectrum of myeloid precursors, including myelocytes, metamyelocytes, promyelocytes, and occasional blasts, a picture highly suggestive of chronic myeloid leukemia. Yet the lymphocyte percentage of 24% appeared deceptively normal on its face. The absolute lymphocyte count told a different story: with total leukocytosis of 292.74 × 10³/μL, the 24% fraction corresponded to an absolute lymphocyte count of 70.26 × 10³/μL, a figure dramatically above normal. This distinction between relative and absolute counts proved pivotal, as it flagged the presence of a second proliferative disorder hiding behind the dominant myeloid picture. Recognizing the myeloproliferative emergency, clinicians started the patient on hydroxyurea from the first day, and over an 18-day course his leukocyte count fell significantly to 11.8 × 10³/μL.

Molecular testing then confirmed the myeloid diagnosis. The patient expressed strong levels of the BCR::ABL1 p210 transcript, the hallmark fusion gene generated by the t(9;22)(q34;q11) chromosomal translocation, along with weak expression of the p190 variant. This translocation fuses the ABL1 gene on chromosome 9 with the BCR gene on chromosome 22, creating the infamous Philadelphia chromosome. The resulting fusion protein exhibits constitutive tyrosine kinase activity, driving uncontrolled proliferation of myeloid cells. Based on these findings, the patient began imatinib, a targeted tyrosine kinase inhibitor, on day 10 of admission at 400 mg daily.

But the diagnostic workup was not finished. Flow cytometry of the peripheral blood, performed to assess blast percentage, revealed a clonal B-cell population expressing CD5, CD19, and CD20, an immunophenotype classic for chronic lymphocytic leukemia. The test was repeated for confirmation and yielded identical results. CLL is defined by the clonal expansion and progressive accumulation of mature B lymphocytes, most of which express the CD5 antigen, infiltrating the peripheral blood, bone marrow, lymphatic tissues, and spleen. Imaging studies added further evidence: abdominal and pelvic ultrasonography identified multiple pathologic lymph nodes, including portacaval nodes up to 15 mm and left mesenteric nodes up to 12 mm in short-axis diameter, all round, lacking the central echogenic hilum of healthy nodes. Splenomegaly was also noted, with a cranio-caudal diameter of 205 mm.

By discharge, the white cell count had normalized to 10.7 × 10³/μL and lactate dehydrogenase had fallen to 363 U/L, indicating reduced cellular turnover. However, anemia had worsened to 7.5 g/dL and thrombocytopenia had developed, with platelets dropping to 69 × 10³/μL, possibly reflecting disease burden or cytotoxic effects of therapy. The lymphocyte percentage was markedly elevated at 82.2%, supporting the concurrent lymphoproliferative diagnosis. After two months of continuous imatinib treatment, the patient showed significant clinical and hematological response, with marked reduction in white cell count and notable improvement in performance status, though persistent lymphocytosis remained. Tragically, approximately two months after treatment initiation, he developed severe community-acquired pneumonia and died of respiratory failure, cutting follow-up short.

The simultaneous occurrence of CML and CLL presents a fascinating biological puzzle. CLL is the most prevalent leukemia in adults across Western countries, with an estimated incidence of 4 to 6 cases per 100,000 individuals annually, and over 70% of patients diagnosed at 65 years or older. CML is the most common myeloproliferative disorder characterized by the BCR::ABL1 fusion gene. Despite both conditions preferentially affecting elderly populations, their coexistence is exceedingly uncommon. Documented presentations include sequential diagnoses, where one malignancy follows the other, and synchronous onset, in which both are identified at the same time. In over half of reported cases, CLL preceded CML, and many of those patients had received chemoimmunotherapy with agents such as fludarabine or chlorambucil, raising the possibility that DNA damage or selection pressures from CLL therapy might contribute to subsequent CML. Notably, the present patient had no history of cytotoxic therapy, making his simultaneous presentation even more enigmatic.

Several hypotheses attempt to explain this biclonal leukemic phenomenon. Cytogenetic studies in some cases show that the two malignancies arise from separate hematopoietic clones: researchers have demonstrated BCR::ABL1 fusion confined exclusively to the myeloid fraction, while monoclonal immunoglobulin gene rearrangement was found only in the lymphoid CLL cells, supporting two distinct malignant clones coexisting rather than a single clone transforming along two lineages. Conversely, other authors speculate that both neoplasms may originate from a single pluripotent hematopoietic stem cell that acquires mutations enabling both myeloid and lymphoid transformation. If BCR::ABL1 occurred in an early progenitor, it could theoretically give rise to both myeloid and lymphoid clones, though direct proof remains lacking. A third mechanism involves microenvironmental effects: BCR::ABL1-positive cells produce cytokines such as interleukin-3, which can stimulate CD34⁺ progenitors and B-lymphoid cells, meaning a CML clone could in theory secrete factors that drive expansion of a B-lymphoid clone, or vice versa.

This case underscores the critical importance of comprehensive diagnostic evaluation when patients present with atypical hematological findings. The peripheral blood smear, flow cytometry, and molecular studies were all pivotal in unraveling the dual diagnosis, and the distinction between relative and absolute lymphocyte counts proved essential to recognizing the second malignancy. The pathogenesis of such rare co-occurrence remains under active debate, with the consensus being that it is heterogeneous: some patients demonstrably arise from separate clones, while others are best explained by a shared stem-cell origin. Genetic instability, environmental triggers, or stochastic events may all contribute to this rare dual leukemogenesis. As the population ages and diagnostic techniques grow more sensitive, clinicians may encounter such dual malignancies more frequently, making awareness of this phenomenon increasingly relevant for hematologists managing elderly patients with complex blood disorders.

Subject of Research: Rare co-occurrence of chronic myeloid leukemia and chronic lymphocytic leukemia in a single patient

Article Title: A Rare Case of Chronic Lymphocytic Leukemia and Chronic Myeloid Leukemia in an Elderly Patient: A Case Report

Article References: Kamandi, M., & Alvandi Fard, M. M. (2026). A Rare Case of Chronic Lymphocytic Leukemia and Chronic Myeloid Leukemia in an Elderly Patient: A Case Report. Clinical Case Reports, 14(10), Article e73136. https://doi.org/10.1002/ccr3.73136

Image Credits: AI Generated

DOI: 10.1002/ccr3.73136

Keywords: chronic myeloid leukemia, chronic lymphocytic leukemia, BCR::ABL1, flow cytometry, hematology, case report, Rare, Case, Chronic, Lymphocytic, Leukemia, Myeloid

IκBζ, encoded by the NFKBIZ gene, is not a conventional inhibitor. While classical IκB proteins sit in the cytoplasm and restrain NF-κB until an inflammatory signal arrives, IκBζ is induced at the transcriptional level during the first wave of the inflammatory response and then accumulates in the nucleus, where it shapes the second wave of inflammation in cooperation with the p65 and p50 subunits of NF-κB. Recent structural and functional work has expanded this picture considerably: IκBζ can act as a coactivator of POU-family lineage transcription factors through two distinct interaction domains, and in melanoma cells it has been shown to enhance STAT3-dependent transcription at selected loci while repressing other targets through recruitment of chromatin-modifying enzymes such as EZH2 and HDAC3. This context-dependent versatility is precisely what made its role in B cell malignancies so intriguing and so poorly defined.

Aberrant IκBζ expression had already been implicated in lymphoid cancers. In a subset of activated B cell-like diffuse large B cell lymphomas, mutations in the 3′ untranslated region of NFKBIZ stabilize the mRNA and drive elevated protein levels, and NFKBIZ has emerged as a selective dependency gene in both B and T cell lymphomas across large-scale functional genomic screens. In chronic lymphocytic leukemia, the same 3′ UTR mutation appears only occasionally, but post-transcriptional mechanisms appear to be at work: when leukemic cells are stimulated in vitro with Toll-like receptor ligands that mimic microenvironmental signals, NFKBIZ mRNA rises sharply and IκBζ protein climbs even more dramatically. Higher IκBζ expression is found in a subset of CLL samples carrying negative prognostic markers, and pharmacologically blocking this axis with inhibitors such as dimethyl fumarate has shown significant therapeutic activity in preclinical models. What remained missing was the fundamental piece of the puzzle: the identity of the genes that IκBζ directly controls in these cells.

To close that gap, the team applied two complementary genome-binding technologies, chromatin immunoprecipitation followed by sequencing and the more recently developed CUT&Tag method, to B lymphocytes isolated from the peripheral blood of healthy donors and CLL patients. Unstimulated cells served as an internal control because they contain little to no IκBζ protein, whereas stimulation with CpG oligonucleotides, which activate the innate DNA-sensing receptor TLR9, induces high levels of the protein together with robust NF-κB activation. The two platforms behaved very differently in scale: ChIP-seq recorded roughly a fifty-five-fold increase in IκBζ binding sites after stimulation, while CUT&Tag showed about a three-fold increase, a discrepancy the authors attribute to protocol differences, with double-crosslinked ChIP capturing both direct and unstable interactions across millions of cells and native-condition CUT&Tag excelling at identifying the strongest, most direct binding events from just a few hundred nuclei.

By intersecting the consensus peak sets from both platforms at matching genomic coordinates, requiring at least 100 base pairs of reciprocal overlap, the researchers defined 421 high-confidence IκBζ binding sites that were reproducible across technologies and independent patient cohorts. Genomic annotation revealed a consistent and striking shift toward promoter-proximal binding upon stimulation: in CUT&Tag, the fraction of peaks at promoters rose from 60.8 percent to 69.0 percent, and in ChIP-seq it jumped from 9.3 percent to 33.1 percent, while intronic and intergenic peaks declined on both platforms. At the gene level, the intersection of newly gained targets across both datasets identified 654 genes recruited to IκBζ upon CpG stimulation, and only a single gene, the kinase HUNK, was lost, underscoring that the response is dominated by gain rather than loss of occupancy, exactly as expected given the near-absence of the protein in resting cells.

Pathway enrichment analysis of the 394 unique genes associated with the 421 high-confidence peaks, conducted across seven curated databases, converged on eight non-redundant biological themes. The strongest signal was B cell receptor signaling, followed closely by TNF-α/NF-κB signaling, IL-2/STAT5 signaling, and chemokine signaling. Apoptosis appeared at two levels of resolution, including the specific BCL-2-regulated program through BH3-only protein interaction, consistent with the identification of the anti-apoptotic gene BCL2 itself among the targets. Perhaps most unexpectedly, the ATM-dependent DNA damage response was significantly enriched, pointing to an unanticipated connection between IκBζ-regulated chromatin and genomic stress programs in leukemic cells. A stricter differential binding analysis, requiring genes to satisfy consensus gain, ChIP-seq differential gain, and CUT&Tag differential gain with a false discovery rate below 0.05, distilled the list to 39 top-tier candidate targets, including B cell transcriptional regulators such as FOXP1, BATF, TCF4, TCF7 and POU2F2, NF-κB pathway components such as TNIP1, TNFSF4 and CD40LG, and chromatin-modifying factors including NCOR2 and SMARCE1.

Functional validation followed. The team first showed that dimethyl fumarate, a drug known to blunt the TLR/IκBζ axis, reduced CpG-induced expression of candidate targets in primary CLL cells. They then deployed CRISPR-Cas9 gene editing to knock out NFKBIZ in seven fresh primary leukemic samples. Real-time PCR demonstrated that two targets, NFKB2, which encodes the p100/p52 precursor of the non-canonical NF-κB pathway, and CXCR5, a chemokine receptor overexpressed in CLL compared with normal circulating B cells, were no longer induced in the absence of IκBζ. BATF showed a trend toward reduced induction, while FOXP1, whose locus carried multiple IκBζ binding regions, was not clearly dependent on the factor, suggesting that its regulation involves multiple converging transcriptional activators, in line with previous reports of complex multi-input control at this gene in B cell malignancies.

The chromatin-level analysis added a crucial layer of mechanistic insight. By profiling three histone marks in the same samples, H3K27ac for active enhancers and promoters, H3K4me3 for active promoters, and H3K27me3 for polycomb-mediated repression, the researchers found that IκBζ binding sites in unstimulated CLL cells occupied a heterogeneous, partly bivalent chromatin environment. After CpG stimulation, these sites underwent a coordinated epigenetic transition: H3K27ac rose sharply with focused enrichment at peak centers, H3K27me3 fell substantially, and H3K4me3 increased, indicating resolution of bivalency and activation of promoter-proximal regulatory regions. Notably, at the 86 statistically significant differentially gained peaks, H3K27ac was already detectable before IκBζ arrived, implying that the factor is preferentially recruited to loci carrying pre-existing partial activity rather than to fully silent regions, and that its recruitment coincides with, and may contribute to, a further gain of active marks.

Motif analysis supplied an internal validation of the entire dataset and a genuine surprise. Across all five peak sets examined, NF-κB family motifs, including p65/RelA, p52/NFKB2, REL and RELB, were consistently among the most enriched and centrally positioned, confirming IκBζ’s role as an NF-κB co-regulator. But POU-domain motifs, particularly OCT2/POU2F2, emerged as a CpG-specific signature: in the highest-confidence peak set, POU2F2 ranked as the single most significantly centrally enriched motif overall, with an adjusted p value of 1.8 × 10⁻¹⁸, edging out NFKB2 itself. Given OCT2’s established role in driving immunoglobulin transcription and B cell differentiation, this suggests that inflammatory stimulation redirects IκBζ toward regulatory elements co-occupied by lineage-specific transcription factors, a relationship that recent work in B cell lymphoma cell lines, where IκBζ was shown to be a dual-use coactivator of NF-κB and POU factors, now appears to extend into primary human leukemia.

Comparison with healthy donor B cells showed that much of this program is not leukemia-specific. CpG stimulation drove a conserved redistribution of IκBζ toward promoters in normal B cells as well, though the final promoter fraction remained far lower than in leukemic cells, 30.8 percent versus 69.0 percent, indicating that CLL mounts a quantitatively amplified version of a normal TLR9 response. A core set of targets, including FOXP1, BATF, NFKB2, TCF7 and TNFSF4, was gained in both systems, providing strong cross-system validation. Finally, experiments in mice lacking Nfkbiz specifically in the B cell lineage confirmed BATF as the single most robustly validated direct target: it was induced by CpG in wild-type B cells and significantly reduced when IκBζ was absent, while genes such as ECE1 and PIK3C2B were derepressed, revealing that IκBζ can also function as a repressor at selected loci. Taken together, the study positions IκBζ as a central transcriptional hub that couples TLR9-driven inflammation, B cell receptor signaling, lineage-specific transcription and migratory behavior in chronic lymphocytic leukemia, and strengthens the rationale for targeting this axis therapeutically in patients whose leukemic cells show the highest IκBζ levels.

Subject of Research: Genome-wide identification of IκBζ transcriptional target genes in chronic lymphocytic leukemia and normal B cells

Article Title: IκBζ target genes in chronic lymphocytic leukemia

Article References: Sana, I., Meloni, M., Genova, F., Mantione, M. E., Tascini, A. S., Zapparoli, E., Carbone Faccin, G., Paschaloudi, D., Del Nero, M., Lenzi, C., Ranghetti, P., Perotta, E., Scarfò, L., Ghia, P., & Muzio, M. (2026). IκBζ target genes in chronic lymphocytic leukemia. iScience, 29(11), Article 117828. https://doi.org/10.1016/j.isci.2026.117828

Image Credits: AI Generated

DOI: 10.1016/j.isci.2026.117828

Keywords: chronic lymphocytic leukemia, IκBζ, NFKBIZ, NF-κB, TLR9, CpG stimulation, ChIP-seq, CUT&Tag, BATF, FOXP1, NFKB2, B cell signaling

The core problem CytoVI addresses is that antibody-based measurements are relative, not absolute. In flow cytometry, a protein’s signal depends on which fluorophore is attached to the antibody; in mass cytometry, on which heavy-metal isotope is used. Because laboratories choose different reporter molecules, staining protocols and antibody panels, the same cell type can look strikingly different across experiments. Batch effects arising from instrument performance, reagent lots and sample handling further obscure biology. Comparative studies across the vast public repositories of cytometry data have therefore been largely impractical, since different studies interrogate different marker sets with different technologies.

CytoVI is a variational autoencoder, a probabilistic latent variable model in which an encoder neural network compresses each cell’s protein expression profile into a low-dimensional latent vector that represents the cell’s intrinsic state, complete with an associated uncertainty. A decoder network then reconstructs the original protein expression from that embedding, conditioned on observed nuisance covariates such as batch, technology or antibody panel. By optimizing the evidence lower bound, a combination of a reconstruction term and a Kullback–Leibler regularization, the model learns embeddings that are corrected for technical variation while retaining biological signal. Depending on the expected heterogeneity of the sample, the latent space is assigned either an isotropic Gaussian prior or a more expressive mixture of Gaussians, which can optionally be informed by existing cell type labels in difficult integration scenarios.

Because the model is generative, it does far more than integrate. The trained decoder can produce batch-corrected expression estimates, test for differentially expressed proteins within a Bayesian framework, and, crucially, impute proteins that were never measured. When two experiments use partially overlapping antibody panels, the encoder reads only the shared backbone markers while the decoder reconstructs the union of all markers, effectively filling in the gaps with probabilistic estimates that carry explicit uncertainty. The same counterfactual decoding logic allows CytoVI to impute morphological features such as forward and side scatter into mass cytometry data, and even to impute transcriptomes into flow cytometry datasets when paired CITE-seq measurements are available as a reference.

The authors validated the model through a series of rigorous benchmarks. Posterior predictive checks showed that CytoVI faithfully reproduces the statistical properties of flow cytometry, mass cytometry and CITE-seq data. In integration tests on replicate peripheral blood mononuclear cell samples measured in different batches, CytoVI removed technical variation while preserving cell type structure, performing at least on par with state-of-the-art tools such as cyCombine, FastMNN and Harmony, and avoiding the residual batch effects those methods left in specific immune compartments. The model remained robust even when more than two-thirds of the markers in one batch were masked, and training stayed computationally manageable, taking under 35 minutes for one million cells on a single GPU.

To demonstrate the scale of insight the approach enables, the team assembled an integrated B cell maturation atlas from mass cytometry data spanning twelve partially overlapping antibody panels. By controlling for batch and imputing non-overlapping markers, CytoVI characterized 350 surface proteins across transitional, naive and memory B cell compartments. Trajectory modeling with diffusion maps and CellRank revealed the differentiation path from transitional B cells toward class-switched memory cells, and the model’s differential expression module pinpointed proteins associated with immunoglobulin class-switching, including CD62L, CD71 and CD100, molecules known to mediate lymph node migration, antigen specificity and B cell–T cell communication.

The clinical potential of the method became apparent in analyses of patient cohorts. In a study of lymph node T cell infiltrates from 63 patients with B cell non-Hodgkin lymphoma, profiled with two overlapping flow cytometry panels, CytoVI’s label-free differential-abundance analysis automatically identified disease-associated T cell states. It reproduced known findings, such as follicular helper T cell enrichment in follicular lymphoma, but also resolved a proliferating population as predominantly CD8-positive T cells and uncovered a small cluster of CD4/CD8 double-negative T cells enriched in diffuse large B cell lymphoma and mantle cell lymphoma that the original manual analysis had missed. By integrating the flow data with paired CITE-seq measurements, the team imputed transcriptomes and showed that these double-negative cells are in fact cytotoxic Vδ1 gamma-delta T cells, a population previously reported to be enriched in lymphoma patients.

Perhaps most strikingly, CytoVI was applied to routine diagnostic flow cytometry for chronic lymphocytic leukemia. Training a reference model on a small set of patients and controls, the researchers used transfer learning to map new, unseen diagnostic samples into the reference latent space without retraining. Automatically detected CLL cell frequencies correlated strongly with expert hematologist annotations, and the kappa-to-lambda light-chain ratio computed within the automatically classified cells captured the monoclonality that is a diagnostic hallmark of the disease. Combining these two features in a simple classifier distinguished CLL patients, including those with minimal residual disease, from controls with an area under the curve of about 0.74, a task that remains challenging even for experts.

The authors frame CytoVI as a step toward a model-centric view of cytometry, analogous to the shift already underway in single-cell transcriptomics. Because cytometry is destructive and restricted to predefined panels, proteins absent from an original experiment are normally lost forever; CytoVI’s probabilistic imputation breathes new life into archived datasets and could support community-scale protein atlases built from conventional assays. With intrinsic uncertainty estimates suited to privacy-sensitive clinical deployment, interoperability with Scanpy workflows, and the ability to fuse the scale of cytometry with the molecular resolution of single-cell genomics, the model lays groundwork for AI-powered cytometry that could accelerate biomarker discovery, standardize diagnostic interpretation and systematically chart cellular states across health and disease.

Subject of Research: Deep generative modeling for unified analysis of antibody-based single-cell data

Article Title: CytoVI: deep generative modeling of antibody-based single cell data

Article References: Ingelfinger, F., Levy, N., Ergen, C., Bakulin, A., Becker, A., Boyeau, P., Kim, M., Ditz, D., Dirks, J., Maaskola, J., Wertheimer, T., Zeiser, R., Widmer, C. C., Amit, I., & Yosef, N. (2026). CytoVI: deep generative modeling of antibody-based single cell data. Nature Methods, 23(10), 2054-2065. https://doi.org/10.1038/s41592-026-03224-5

Image Credits: AI Generated

DOI: 10.1038/s41592-026-03224-5

Keywords: CytoVI, flow cytometry, mass cytometry, CITE-seq, deep generative model, variational autoencoder, batch correction, protein imputation, B cell atlas, non-Hodgkin lymphoma, chronic lymphocytic leukemia, scvi-tools

The study, published in Supportive Care in Cancer, was led by Syed E. Pasha of the University of Houston and HCA Houston Healthcare Kingwood, together with colleagues from MountainView Hospital and Texas Oncology centers. The team set out to answer a deceptively simple question: do patients with diffuse large B-cell lymphoma, an aggressive and rapidly treated lymphoma, experience different kidney outcomes than patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, an indolent disease that often smolders for years before requiring therapy? Comparative renal data between these two populations had been scarce, despite the fact that both cancers are common and both are treated with regimens known to stress the kidneys.

To answer the question, the researchers turned to the TriNetX Global Collaborative Network, a federated database drawing de-identified electronic health records from 143 healthcare organizations. Data were extracted on May 9, 2025. Adults with a coded diagnosis of diffuse large B-cell lymphoma or of chronic lymphocytic leukemia and small lymphocytic lymphoma were identified using standard ICD-10 diagnostic codes. To make the two groups as comparable as possible, the investigators used a statistical technique called propensity score matching, pairing each patient with a counterpart from the other cohort who shared the same age, sex, race, and ethnicity. This one-to-one matching produced two demographically indistinguishable groups, with standardized mean differences between them ranging from just 0.001 to 0.038, values so small they indicate near-perfect balance.

The final analysis included 19,438 patients, evenly split with 9,719 in each cohort. Kidney outcomes were tracked from the first day after the index diagnosis through each patient’s available follow-up, an open-ended window rather than a fixed observation period. The researchers looked for two distinct conditions: acute kidney injury, the sudden loss of renal function that can develop within hours or days, and chronic kidney disease, the gradual, often irreversible decline in filtration capacity that unfolds over months and years. Statistical comparisons relied on two-proportion z-tests, generating risk differences, risk ratios, and odds ratios with 95 percent confidence intervals.

The results revealed a fascinating split. Acute kidney injury struck 22.9 percent of the diffuse large B-cell lymphoma patients compared with 20.9 percent of the chronic lymphocytic leukemia and small lymphocytic lymphoma group. That two-percentage-point gap was statistically significant, with a risk ratio of 1.094 and an odds ratio of 1.122, and a p-value of 0.001. In other words, the aggressive lymphoma carried a modestly higher risk of sudden renal failure. The pattern flipped for chronic kidney disease. Here, 18.8 percent of the lymphoma patients developed the condition versus 22.7 percent of the leukemia and indolent lymphoma group, a negative risk difference of 4.0 percent, with a risk ratio of 0.825 and an odds ratio of 0.785, and a p-value below 0.001. The slower cancer, paradoxically, left a heavier mark on long-term kidney health.

The biology behind this divergence makes intuitive sense when one considers how each disease and its treatment unfold. Diffuse large B-cell lymphoma grows quickly and is typically treated with intensive chemoimmunotherapy, most commonly regimens built around rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone. Rapid tumor cell death can trigger tumor lysis syndrome, a cascade in which potassium, phosphate, and uric acid flood the bloodstream and crystallize in renal tubules, a well-documented cause of acute kidney injury. High-dose chemotherapy agents themselves, along with the infections, dehydration, and intensive care admissions that can accompany aggressive treatment, all add to the short-term renal assault.

Chronic lymphocytic leukemia, by contrast, is a disease of accumulation and time. Patients frequently live with it for a decade or more, and even those who never require treatment face aging kidneys, cumulative exposure to nephrotoxic drugs across successive lines of therapy, and immune complications. Modern targeted therapies such as ibrutinib, which has transformed outcomes in this disease, carry their own renal baggage; real-world analyses of hundreds of treated patients have documented a spectrum of toxicities that can include hypertension and kidney dysfunction. Over years of surveillance, treatment, and comorbidity, the indolent disease’s patient population gradually accrues the chronic damage that shows up as chronic kidney disease. The new data, showing a 22.7 percent chronic kidney disease rate in this group, align with that clinical picture.

The authors are careful to frame their findings as hypothesis-generating rather than definitive. The matching algorithm balanced demographics but did not capture comorbidities such as diabetes, hypertension, or pre-existing renal impairment, all of which are powerful drivers of kidney disease and may differ systematically between the two cancer populations. Follow-up duration was also not matched, and the open-ended observation window means patients in one group may simply have been watched longer. Absolute differences between the cohorts were small, in the range of two to four percentage points, and the study relied on administrative diagnostic codes rather than laboratory-verified kidney function measures. The research was supported in whole or in part by HCA Healthcare, though the authors declare no competing interests, and the views expressed are those of the authors alone.

Even with those caveats, the study carries practical weight for the growing field of onco-nephrology, the discipline that sits at the intersection of cancer care and kidney medicine. Acute kidney injury in patients with hematological malignancies is known to worsen remission rates and survival, and chronic kidney disease constrains which cancer therapies a patient can safely receive, since many agents require dose adjustment or are contraindicated in renal impairment. If the pattern observed here holds up, supportive care pathways might reasonably emphasize vigilant short-term renal monitoring, hydration protocols, and uric acid management around the intensive treatment phases of aggressive lymphoma, while building durable long-term nephrology follow-up into the care of chronic lymphocytic leukemia survivors, whose kidneys face a marathon rather than a sprint.

What comes next is confirmation. The authors themselves call for comorbidity-adjusted analyses and prospective studies to verify whether the renal risk differences survive when diabetes, hypertension, baseline kidney function, and treatment exposure are properly accounted for. Until then, the message for clinicians is one of heightened awareness rather than alarm: both cancer subtypes deserve deliberate attention to the kidneys, but the timing and nature of that attention may need to differ. A single dataset of nearly twenty thousand matched patients cannot settle every question, but it has usefully drawn a map, pointing oncologists toward the moments in each disease trajectory where the kidneys are most vulnerable, and reminding the wider medical community that surviving cancer is only half the story, with protecting the organs that carry patients through survivorship being the other half.

Subject of Research: Comparative renal outcomes of acute kidney injury and chronic kidney disease in diffuse large B-cell lymphoma versus chronic lymphocytic leukemia/small lymphocytic lymphoma

Article Title: Renal risk differences between diffuse large B-cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: implications for supportive oncology care

Article References: Pasha, S. E., Khalique, S., Haddadin, R., Mazharuddin, S., & Khoury, P. N. (2026). Renal risk differences between diffuse large B-cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: implications for supportive oncology care. Supportive Care in Cancer, 34(10), Article 1029. https://doi.org/10.1007/s00520-026-11256-y

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11256-y

Keywords: diffuse large B-cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, acute kidney injury, chronic kidney disease, supportive oncology, onco-nephrology, nephrotoxicity, TriNetX, propensity score matching, real-world data, tumor lysis syndrome

The research, led by Min Min, Jun Zhang, Jingjing Wang, Yin Chen, and Hewei Luan of the Department of Laboratory Medicine at Jurong Hospital, Jiangsu University, in Zhenjiang, China, set out to clarify what LAIR1 actually does in CLL. LAIR1 is an inhibitory receptor expressed on the surface of many immune cells, including natural killer cells, T cells, B cells, and myeloid lineages. Its cytoplasmic tail carries immunoreceptor tyrosine-based inhibitory motifs (ITIMs), which, upon ligand binding, recruit phosphatases that blunt cellular activation signals. In the context of cancer, inhibitory receptors have typically been viewed through the lens of immune evasion, as tumors can exploit such pathways to escape immune surveillance. The new findings, however, suggest that in CLL the story may be more nuanced, with LAIR1 expression levels correlating with disease outcome in a way that hints at a protective role.

To dissect the cellular landscape of CLL, the team began with single-cell RNA sequencing analysis, a technique that allows researchers to profile gene expression in individual cells rather than in bulk tissue samples. Using uniform manifold approximation and projection (UMAP) for dimensionality reduction and principal component analysis to characterize transcriptional variation, they mapped the cellular signatures within CLL samples and identified the key cell populations populating the leukemic microenvironment. Among these, macrophages emerged as a particularly important population, exhibiting the highest expression of LAIR1 of any cell type examined. This observation is notable because tumor-associated macrophages are increasingly recognized as central architects of the tumor microenvironment in many malignancies, shaping immune responses, supporting tissue remodeling, and influencing treatment response.

With the cellular context established, the investigators turned to comparative expression analysis. Drawing on public datasets, including resources from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA), they compared LAIR1 expression between CLL samples and healthy control samples. The results were consistent across bioinformatic and experimental approaches: LAIR1 expression was significantly decreased in CLL compared with controls. This downregulation raised an immediate clinical question. If LAIR1 is lost as the disease develops, does the degree of loss carry prognostic weight? To answer this, the team stratified CLL patients into two groups according to the optimal cutoff value of LAIR1 expression and compared their survival outcomes using Kaplan-Meier analysis.

The survival analysis delivered a striking result. Patients in the low LAIR1 expression group had significantly worse prognosis than those whose tumors retained higher levels of the receptor. In other words, the more LAIR1 expression was diminished, the poorer the clinical outlook. This kind of expression-outcome relationship does not by itself prove causation, but it provides a compelling correlation that justified the next phase of the study: directly testing what LAIR1 does to leukemic cells when its expression is experimentally restored. Correlative findings in cancer genomics frequently dissolve under functional scrutiny, so the team designed a series of laboratory experiments to move from association toward mechanism.

The functional work centered on a human CLL cell line. The researchers constructed LAIR1 overexpression variants of these cells and confirmed that the receptor was genuinely upregulated at both the messenger RNA and protein levels, using real-time quantitative polymerase chain reaction (RT-qPCR) and Western blotting respectively. RT-qPCR amplifies complementary DNA copies of specific transcripts to quantify gene expression with high sensitivity, while Western blotting uses antibody-based detection to measure protein abundance, and agreement between the two methods gave the team confidence that their engineered cell lines faithfully reflected LAIR1 overexpression. With the model system validated, they proceeded to the central question: what happens to CLL cells when LAIR1 is abundantly present?

The answer came from flow cytometry, a technique that passes thousands of individual cells in rapid succession through laser beams, allowing researchers to quantify fluorescent signals attached to specific cellular features. By staining cells with propidium iodide (PI), a dye whose uptake reflects DNA content, the team could determine the distribution of cells across the phases of the cell cycle. By applying annexin-based apoptosis assays, they could measure the fraction of cells undergoing programmed cell death. The results were clear and internally consistent. CLL cells engineered to overexpress LAIR1 displayed a shortened S phase, the portion of the cell cycle devoted to DNA replication, and exhibited significantly increased rates of apoptosis. In effect, restoring LAIR1 pushed the leukemic cells away from proliferation and toward self-destruction.

These findings carry conceptual weight because they link an immune inhibitory receptor to the core proliferative machinery of the cancer cell itself. A shortened S phase combined with elevated apoptosis suggests that LAIR1 overexpression disrupts the carefully balanced cell cycle regulation that allows CLL cells to accumulate slowly over years. CLL is notorious for its dependence on anti-apoptotic signaling, particularly through the BCL-2 family of proteins, which is precisely why BCL-2 inhibitors such as venetoclax have proven so effective in the clinic. The observation that LAIR1 overexpression increases apoptotic rates places the receptor on the same functional axis as the pathways that current drugs target, albeit from a different molecular entry point. Whether LAIR1 acts directly on cell cycle regulators or indirectly through downstream signaling from its ITIM motifs remains an open question that the study does not fully resolve, but the phenotypic effect is unambiguous in the experimental system used.

The macrophage connection adds a further layer of biological interest. The single-cell analysis identified macrophages as the highest LAIR1-expressing cells in the CLL microenvironment, which raises the possibility that the receptor’s influence on disease progression is mediated, at least in part, through the tumor microenvironment rather than through the malignant B cells alone. Tumor-associated macrophages can adopt polarized states that either support or suppress tumor growth, and inhibitory receptors like LAIR1 are key regulators of macrophage activation. A scenario in which reduced LAIR1 expression licenses macrophages toward a more tumor-permissive state, while simultaneously removing a brake on leukemic cell cycling, would fit the clinical observation that low LAIR1 predicts worse survival. Disentangling these cell-intrinsic and microenvironmental contributions will be an important task for future studies.

The authors are careful to frame their conclusions appropriately, describing the work as offering a novel reference for the effect of LAIR1 in CLL rather than as an immediate therapeutic blueprint. The study was supported by the Jurong City Social Development Science and Technology Planning Project under grant number ZA42203, and the authors declared no competing interests. Published open access on 1 September 2026 in Annals of Hematology, the paper arrives at a moment when the field is actively searching for biomarkers that can refine risk stratification beyond the existing clinical and genetic markers, such as immunoglobulin heavy chain variable region mutation status and cytogenetic abnormalities. If LAIR1 expression can be validated as a prognostic marker in larger, independent cohorts, it could eventually help clinicians identify which patients need earlier intervention. And if the functional findings hold up, pharmacological strategies aimed at restoring or mimicking LAIR1 signaling might one day complement BTK and BCL-2 inhibition, attacking the disease from yet another angle. For now, the study stands as a reminder that some of the most informative clues about cancer biology come from molecules that were hiding in plain sight on the surface of the immune system’s own cells.

Subject of Research: The role of the LAIR1 immune receptor in regulating cell cycle progression and apoptosis in chronic lymphocytic leukemia

Article Title: LAIR1 regulated the development of chronic lymphocytic leukemia by modulating cell cycle and apoptosis

Article References: Min, M., Zhang, J., Wang, J., Chen, Y., & Luan, H. (2026). LAIR1 regulated the development of chronic lymphocytic leukemia by modulating cell cycle and apoptosis. Annals of Hematology. https://doi.org/10.1007/s00277-026-07263-y

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07263-y

Keywords: chronic lymphocytic leukemia, LAIR1, cell cycle, apoptosis, single-cell RNA sequencing, macrophages, tumor microenvironment, flow cytometry, Kaplan-Meier survival analysis, RT-qPCR, Western blot, hematology

Regulators have moved quickly. After a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use in June 2026, the European Commission approved pirtobrutinib in August 2026 for adults with CLL across all lines of therapy, and an equivalent decision from the US Food and Drug Administration is anticipated in the second half of 2026. An accompanying editorial by Davids argued that the two trials open the door for noncovalent BTK inhibition as initial therapy. On the surface, the case seems overwhelming: a drug that works at least as well as the incumbent, with dramatically better cardiovascular tolerability, seems destined to become the new default first choice.

But a correspondence published in Annals of Hematology by Boyi Chen and Shenxian Qian throws a careful, technically grounded brake on that enthusiasm. The authors highlight what they call a sequencing asymmetry, a structural imbalance in the evidence that neither of the new trials was designed to address. The order in which the two BTK inhibitor classes are given, they argue, matters enormously, and only one of the two possible orders is currently supported by randomized evidence. That order is the covalent-first sequence, and the argument for preserving it rests on the molecular biology of drug resistance as much as on clinical trial data.

The covalent BTK inhibitors, including ibrutinib, acalabrutinib and zanubrutinib, bind permanently to a cysteine residue at position 481 of the BTK kinase. Resistance to these drugs most often emerges through the C481S mutation, which replaces that cysteine with serine and blocks covalent attachment while leaving the binding pocket otherwise intact. Crucially, pirtobrutinib does not depend on covalent chemistry, so it retains activity against C481-mutant BTK. In the phase 1/2 BRUIN study, pirtobrutinib achieved a 73.3 percent response rate and a median progression-free survival of 19.6 months in patients whose disease had progressed on a covalent inhibitor, regardless of C481 status. In the phase III BRUIN CLL-321 trial, it outperformed idelalisib plus rituximab or bendamustine plus rituximab in this setting, with a hazard ratio of 0.54 and a median progression-free survival of 14.0 versus 8.7 months. A patient who begins treatment with a covalent inhibitor therefore keeps a rational, evidence-backed exit ramp if resistance develops.

The reverse sequence has no comparable data, and the resistance mechanisms give concrete reason for concern. Work by Wang and colleagues showed that acquired resistance to pirtobrutinib does not arise through C481 but through a distinct set of kinase-domain mutations: V416L, A428D, M437R, T474I and L528W. Of these, A428D and L528W conferred in vitro cross-resistance to ibrutinib and prevented multiple covalent BTK inhibitors from inhibiting the mutant enzyme. In other words, a patient who progresses on first-line pirtobrutinib may harbor leukemic clones that have compromised not just one drug but much of the covalent class, the very class that currently anchors relapse management. Notably, no patient in the Wang series acquired a new C481 mutation on pirtobrutinib, indicating that the two drug classes select largely distinct mutations, and that the mutations selected by the noncovalent agent can reduce sensitivity to covalent drugs. As Mato and colleagues observed in the original BRUIN publication, no information is currently available on the efficacy of covalent BTK inhibitors in patients who receive pirtobrutinib first and in whom resistance develops.

Davids offers a reasonable counterargument: many older patients with comorbidities may need only one or two lines of therapy over their remaining lifetime, making downstream resistance a less salient concern. For that subgroup, Chen and Qian concur that first-line pirtobrutinib is defensible, since a single effective line may be the realistic horizon. But CLL is not uniformly a disease of the very old. Younger patients, and those with unmutated IGHV genes or TP53 aberrations, can expect disease courses lasting ten to twenty years and multiple lines of treatment. Patients with del(17p) were even excluded from the CLL-313 trial. For these individuals, sequencing is not a footnote but the central strategic question, and spending the noncovalent agent first may forfeit options decades before they are needed.

Nor does toxicity, the argument that once favored abandoning covalent inhibitors altogether, justify skipping the class today. The cardiovascular case against ibrutinib has been substantially overtaken by the second-generation covalent agents. Zanubrutinib more than halved the rate of atrial fibrillation compared with ibrutinib in the ALPINE trial, 5.2 percent versus 13.3 percent, while improving progression-free survival, and acalabrutinib reduced atrial fibrillation in the ELEVATE-RR trial, 9.4 percent versus 16.0 percent, with non-inferior efficacy. The covalent-first strategy also preserves later options: beyond pirtobrutinib monotherapy after covalent inhibitor failure, the triplet of pirtobrutinib with venetoclax and rituximab has outperformed venetoclax plus rituximab in previously treated disease in BRUIN CLL-322, with a hazard ratio of 0.547. Frontline pirtobrutinib, by contrast, forgoes at present the only BTK-inhibitor class with phase III-validated salvage value.

The authors are careful to qualify their own argument. The cross-resistance evidence is preclinical, resting on in vitro potency and binding studies, and every patient in the Wang series who developed a non-C481 mutation had prior exposure to ibrutinib, so whether frontline pirtobrutinib selects the same mutational spectrum is unknown. Cross-resistance is also not strictly one-directional, since mutations such as L528W have been reported, less frequently, after covalent inhibitor therapy as well. These uncertainties, the authors stress, argue for caution and surveillance rather than regulatory delay. They also caution against treating BTK degraders, an emerging class of drugs that eliminate BTK rather than merely blocking it, as a ready safety net. Degraders such as NX-2127 can degrade kinase-impaired mutants including L528W, and early-phase studies of BGB-16673 and bexobrutideg report rapid, durable responses, but the evidence remains at the abstract level, pivotal trials are still accruing patients, and A428D can itself confer resistance to degrader therapy.

From this analysis flow four concrete recommendations. First, frontline trials of noncovalent BTK inhibitors should mandate BTK and PLCG2 mutation testing at progression, so the field learns which mutations first-line pirtobrutinib actually selects in previously untreated patients. Second, real-world registries should systematically track responses to covalent agents after pirtobrutinib failure, which the authors identify as the single most urgent evidence gap. Third, routine practice should incorporate BTK and PLCG2 testing whenever a patient progresses on any BTK inhibitor, since the mutational profile at relapse directly informs what can work next. Fourth, forthcoming guideline updates should explicitly address sequencing, and post-pirtobrutinib outcomes should be collected systematically while reverse-sequence data remain absent.

The BRUIN program has undeniably given CLL a highly effective drug, and its first-line efficacy is not in doubt. What remains unknown is what early use may cost at relapse. Until prospective sequencing data emerge, the authors conclude, the uncertainty argues for an individualized, sequencing-aware choice rather than a wholesale shift of the treatment default, particularly for the younger patients whose long disease courses give the order of therapy its greatest weight.

Subject of Research: Treatment sequencing and resistance mechanisms for first-line pirtobrutinib in chronic lymphocytic leukemia

Article Title: Sequencing asymmetry: the case for caution before first-line pirtobrutinib in chronic lymphocytic leukemia

Article References: Chen, B., & Qian, S. (2026). Sequencing asymmetry: the case for caution before first-line pirtobrutinib in chronic lymphocytic leukemia. Annals of Hematology, 105(9), Article 404. https://doi.org/10.1007/s00277-026-07264-x

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07264-x

Keywords: chronic lymphocytic leukemia, pirtobrutinib, BTK inhibitor, drug resistance, treatment sequencing, BTK C481S, kinase-domain mutations, BRUIN trials, cross-resistance, BTK degraders, hematology, clinical trials

The central problem the researchers set out to solve is antigen loss. CD19-directed CAR-T cells work by recognizing the CD19 protein on the surface of malignant B cells, but leukemia cells can survive the assault by reducing or eliminating that surface target. When CD19 disappears from the cell membrane, the engineered T cells have nothing to lock onto, and the tumor slips through. This phenomenon of antigen escape is a well-documented cause of relapse after CAR-T treatment, and it is particularly troublesome in CLL, where response rates have lagged behind those seen in acute lymphoblastic leukemia and large B cell lymphoma. Understanding why CLL cells shed their CD19 so readily has therefore become a major focus of laboratory investigation.

The research team, led by investigators at Fujian Medical University Union Hospital and Ruijin Hospital of Shanghai Jiao Tong University School of Medicine, focused on NOTCH1, a signaling receptor with a complicated reputation in leukemia biology. NOTCH1 mutations are common in CLL and influence how the disease progresses, but the pathway’s role in shaping the tumor’s vulnerability to immunotherapy had not been clearly defined. Using the MEC-1 cell line, a widely used model of CLL, the scientists manipulated NOTCH1 signaling in two complementary ways: genetically, by knocking out the gene, and pharmacologically, by treating the cells with inhibitors. They then measured how these altered leukemia cells fared when confronted with CD19-targeted CAR-T cells in laboratory assays.

The results were unambiguous. Leukemia cells lacking functional NOTCH1 signaling were killed far more effectively by the CAR-T cells than their unmodified counterparts. The difference was not a subtle shift in a culture dish; it represented a profound enhancement of the engineered cells’ killing potency. The team traced the effect to a surprising mechanism: rather than NOTCH1 controlling how much CD19 the leukemia cells produce, it controlled how quickly the cells destroyed the CD19 they had already made.

Here is where the cellular machinery gets intricate. When a CAR-T cell engages a leukemia cell through the CD19 receptor, the leukemia cell responds by pulling CD19 off its surface and shuttling it into internal compartments. Inside the cell, the captured protein is routed to lysosomes, the acidic organelles that function as cellular garbage disposals, where it is degraded. The study showed that NOTCH1 signaling actively promotes this disposal process. In other words, the very act of being attacked triggers the leukemia cell to destroy the molecular flag that the immune cells are aiming at, a form of triggered antigen loss that unfolds rapidly enough to blunt the immune response.

The molecular pathway behind this behavior runs through a transcriptional regulator called HEY1, one of the canonical downstream effectors of NOTCH signaling. When NOTCH1 is active, HEY1 is produced and represses the transcription of a gene called RAB31. RAB31 encodes a small GTPase protein that normally acts as a brake on RAB7, a transporter that governs traffic between late endosomes and lysosomes. With RAB31 suppressed, the RAB7-mediated transport route runs unchecked, and internalized CD19 is efficiently delivered to the lysosome for destruction. The researchers demonstrated that this NOTCH1–HEY1–RAB31–RAB7 axis is essential for the rapid loss of surface CD19 after CAR-T engagement. When any link in that chain is broken, the degradation stalls and CD19 accumulates on the cell surface.

The practical consequences of interrupting this pathway were consistent across the team’s experiments. Both NOTCH1-deficient leukemia cells and cells treated with pharmacological NOTCH inhibitors showed impaired CD19 degradation and higher retention of the antigen on their membranes. That surface retention translated directly into greater susceptibility to CAR-T cell killing. The engineered T cells, presented with more abundant CD19 targets, became more activated, and the researchers measured elevated secretion of effector molecules, the inflammatory proteins such as cytokines and cytotoxic factors that CAR-T cells release when they recognize and attack their targets. The combination of NOTCH1 inhibition and CD19 CAR-T therapy thus produced a stronger immune attack than either approach alone.

Importantly, the team did not confine their findings to laboratory dishes. They evaluated the combination strategy in vivo, using animal models of CLL, and the results supported the mechanistic work: pairing NOTCH1 pathway inhibition with CD19 CAR-T cells enhanced therapeutic efficacy in living systems. The animal study was conducted under institutional ethical approval, and the work was funded by the National Natural Science Foundation of China and several Fujian provincial research programs, reflecting a sustained institutional investment in translational hematology research.

The implications for clinical practice are considerable, though they come with caveats. NOTCH inhibitors exist and have been tested in humans for other indications, which means that a combination regimen of NOTCH blockade followed or accompanied by CD19 CAR-T infusion is a plausible near-term clinical strategy rather than a distant theoretical possibility. If the laboratory findings translate to patients, pretreating CLL with a NOTCH pathway inhibitor could preserve surface CD19 long enough for infused CAR-T cells to achieve deeper and more durable responses, potentially addressing one of the main reasons the therapy underperforms in this disease. The approach also illustrates a broader principle that is reshaping cancer immunotherapy research: the tumor’s own signaling circuits can be rewired to make it a better target, turning resistance mechanisms into therapeutic vulnerabilities.

At the same time, the researchers and the field more broadly will need to navigate real challenges before this combination reaches the clinic. NOTCH signaling plays important roles in normal T cell development and intestinal stem cell maintenance, so systemic inhibition carries known toxicities that must be managed carefully, particularly in patients about to receive engineered T cells whose function depends on healthy immune biology. The current study relied on the MEC-1 cell line and animal models, and primary CLL cells from patients show considerable biological heterogeneity, including variable NOTCH1 mutation status, that could modulate the strategy’s effectiveness. Dosing, sequencing, and timing of the combination will all require careful optimization. Nevertheless, by dissecting the precise chain of molecular events that lets leukemia cells discard their CD19 target under fire, the study offers both a mechanistic explanation for CAR-T resistance in CLL and a concrete, druggable intervention point. It transforms a frustrating clinical problem into a defined biological pathway, and it suggests that the next generation of CAR-T therapy for chronic lymphocytic leukemia may succeed not by building a better T cell, but by first disarming the tumor’s escape route.

Subject of Research: NOTCH1 regulation of CD19 antigen degradation and its impact on CD19 CAR-T cell therapy efficacy in chronic lymphocytic leukemia

Article Title: Targeting the NOTCH1 signaling pathway in chronic lymphocytic leukemia enhances the efficacy of CD19 CAR-T cells

Article References: Zheng, H., Xian, H., Lu, C., Zhang, W., Wang, Y., Wang, M., Lin, S., Chen, S., Huang, Z., Yu, Y., Zheng, Y., Bai, Y., Liu, H., & Xu, Z. (2026). Targeting the NOTCH1 signaling pathway in chronic lymphocytic leukemia enhances the efficacy of CD19 CAR-T cells. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04584-9

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04584-9

Keywords: chronic lymphocytic leukemia, CAR-T cell therapy, CD19, NOTCH1 signaling pathway, antigen loss, HEY1, RAB31, RAB7, lysosomal degradation, immunotherapy resistance, MEC-1, hematology

The headline finding is a paradox that defines modern cancer epidemiology across much of Asia. Total leukemia incidence rose by 50.67 percent over the study period, a figure driven largely by population growth and the aging of hundreds of millions of people into age brackets where blood cancers become more common. Yet when the researchers adjusted for those demographic shifts, using age-standardized rates that allow fair comparison across populations and eras, the burden measured in disability-adjusted life years, or DALYs, actually fell by 16.2 percent. DALYs combine years of life lost to premature death with years lived in disability, offering a composite measure of a disease’s true footprint. A declining age-standardized DALY rate alongside rising raw case counts tells a story of medical progress: more people are being diagnosed, but fewer are dying young or living with severe disability from leukemia than would have been expected three decades ago.

Perhaps the most striking subtype-specific revelation concerns chronic lymphocytic leukemia, or CLL, a slow-growing cancer of B lymphocytes that was once considered comparatively rare in Asian populations. The study found that CLL has emerged as the predominant leukemia subtype in the region, a shift that carries both biological and diagnostic implications. CLL incidence showed a positive correlation with the Socio-demographic Index, a composite measure of income, education, and fertility used by GBD researchers, with a correlation coefficient of 0.32 that reached statistical significance. In plain terms, the wealthier and more developed a country or region, the more CLL appears within its leukemia profile. Whether this reflects genuine differences in disease biology, greater longevity allowing indolent cancers to surface, or simply more sophisticated diagnostic infrastructure detecting cases that would previously have gone unrecognized remains an open question that the epidemiological data alone cannot fully resolve.

The methodological machinery behind these conclusions deserves attention, because it represents the current state of the art in population-level cancer surveillance. The researchers employed joinpoint regression, a statistical technique that identifies points in time where the direction or magnitude of a trend changes significantly, allowing them to detect inflection moments that a simple linear analysis would smooth over. They complemented this with Bayesian age-period-cohort models, a framework that disentangles three intertwined influences on disease rates: the effect of a person’s age, the effect of the calendar era in which they live, and the effect of the birth cohort they belong to, which captures exposures and conditions shared by generations. By fitting these models to historical data, the team generated projections to 2030 that come with quantified uncertainty, a discipline that separates serious forecasting from speculation.

Those projections reveal a divergence that maps almost perfectly onto economic development. The age-standardized incidence rate of CLL is forecast to increase by 1.31 percent in middle Socio-demographic Index regions by 2030, while simultaneously decreasing by 0.98 percent in high SDI regions. This crossover is more than a statistical curiosity. It suggests that countries undergoing rapid development may be entering a phase where lifestyle and environmental transitions, combined with expanding diagnostic capacity, push CLL rates upward, whereas the wealthiest nations, having passed through that transition, are beginning to see their rates plateau or decline. For health ministries across South and Southeast Asia, the implication is that the leukemia challenges of the coming decade will not resemble those of the past one, and planning based on outdated subtype distributions risks misallocating scarce resources.

The risk factor analysis grounds these abstract trends in concrete, modifiable behaviors, and it is here that the study’s regional heterogeneity becomes most vivid. In Lebanon, smoking accounted for 29.0 percent of CLL deaths, a proportion that underscores the established link between tobacco exposure and lymphoid malignancies and points directly to tobacco control as a leukemia prevention strategy. In Kuwait, high body mass index contributed to 24.2 percent of leukemia deaths, highlighting the growing recognition that obesity-related metabolic inflammation is not merely a cardiovascular and diabetes concern but a meaningful cancer risk factor as well. That two different countries, facing different dominant risk factors, show such divergent profiles within a single disease category illustrates why the authors argue so forcefully for region-specific prevention strategies rather than continent-wide prescriptions.

The five subtypes examined behave almost like separate diseases, which in biological terms they largely are. Acute myeloid leukemia, a rapidly progressive malignancy of the myeloid blood cell lineage, demands intensive chemotherapy and often stem cell transplantation, and its burden reflects the availability of sophisticated hematology services. Chronic myeloid leukemia, once a death sentence, was transformed by tyrosine kinase inhibitors in the early 2000s into a manageable chronic condition, and declining mortality trends across Asia partly reflect the diffusion of these targeted therapies. Acute lymphoblastic leukemia remains the most common childhood cancer worldwide, with cure rates in well-resourced pediatric oncology centers now exceeding ninety percent, though outcomes in lower-income settings lag far behind. Chronic lymphocytic leukemia, the study’s newly dominant subtype, often requires no immediate treatment at all, following instead a watch-and-wait approach for many patients. Each subtype therefore responds differently to health system investments, and aggregating them obscures exactly the information policymakers need.

The spatial patterns the study documents across 49 countries and territories, stratified by Socio-demographic Index quintiles, add another layer of nuance. Asia is not a uniform block: it contains some of the wealthiest societies on Earth alongside nations where hematology services remain rudimentary. The estimated annual percentage changes in death rates and DALY rates varied substantially across regions for each subtype, with uncertainty intervals that in some cases crossed zero, signaling genuine ambiguity about trend direction. This heterogeneity is itself a finding. It means that a physician in Tokyo, a public health official in Dhaka, and a researcher in Shanghai are effectively confronting different epidemiological landscapes under the same disease umbrella, and that continental averages, however useful for global comparison, conceal the local realities where care is actually delivered.

What makes this analysis resonate beyond hematology is what it reveals about the epidemiological transition now sweeping through low- and middle-income countries. As infectious disease mortality falls and life expectancy rises, cancer becomes the frontier, and leukemia, with its subtype-specific dependence on age structure, diagnostics, and treatment access, serves as a sensitive barometer of that transition. The Shanghai-based team, supported by the Program of Shanghai Academic Research Leader, has produced a dataset that other regions could emulate, and their central message is hard to overstate: the era of treating leukemia as a single public health problem is over. The rising tide of new diagnoses will continue as Asia’s population ages, but the falling tide of age-standardized death and disability shows that prevention, early detection, and targeted therapy are working where they reach people. The task for the next decade, the data suggest, is ensuring they reach everyone, from the smoking-cessation clinics of the Levant to the obesity-prevention programs of the Gulf to the diagnostic laboratories of the developing economies where CLL’s rise is only beginning.

Subject of Research: Epidemiological trends and spatial patterns of five leukemia subtypes across Asia from 1990 to 2021 based on Global Burden of Disease data

Article Title: Temporal trends and spatial patterns of leukemia subtypes in Asia, 1990–2021: a global burden of disease study

Article References: Jiang, N., Yao, R., Zhou, H., Yan, W., Liu, W., Dai, X., Jin, Z., Yu, G., Kang, M., & Yin, J. (2026). Temporal trends and spatial patterns of leukemia subtypes in Asia, 1990–2021: a global burden of disease study. Annals of Hematology. https://doi.org/10.1007/s00277-026-07232-5

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07232-5

Keywords: leukemia, chronic lymphocytic leukemia, Global Burden of Disease, Asia, cancer epidemiology, Socio-demographic Index, DALYs, acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, risk factors, disease projection

Zanubrutinib belongs to a class of targeted drugs known as Bruton’s tyrosine kinase inhibitors, or BTK inhibitors, which block a signaling protein that B cells, the immune cells that turn malignant in chronic lymphocytic leukemia, rely on for survival and proliferation. First-generation inhibitors such as ibrutinib transformed outcomes for this patient population but carried a burden of off-target effects, because they also inhibited related kinases including those involved in cardiac rhythm, platelet aggregation, and other signaling pathways. Zanubrutinib was engineered for greater selectivity, binding BTK more completely while sparing neighboring targets, and the new cohort study set out to test whether that improved pharmacological profile translates into better tolerability and sustained disease control outside the carefully curated environment of a clinical trial.

The researchers interrogated treatment patterns across the full cohort with unusual granularity. Therapy was discontinued in 76 patients, or 18.5 percent of the total, but the reasons tell an encouraging story. Disease progression accounted for only 32 discontinuations, or 7.8 percent of all patients, meaning the vast majority of patients who stopped the drug did so for reasons unrelated to treatment failure. Patient preference led 25 patients, or 6.1 percent, to discontinue, adverse events prompted 15 patients, or 3.7 percent, to stop, and four patients, or 1.0 percent, died of unknown causes. In an era when treatment duration on continuous oral therapy is a key measure of a drug’s real-world value, these numbers suggest that zanubrutinib keeps patients on treatment and keeps their disease in check for extended periods.

Perhaps the most clinically consequential finding concerns dose reductions, a topic that has generated anxiety among both oncologists and patients. Forty-six patients, or 11.2 percent of the cohort, required at least one dose reduction, most commonly because of adverse events, which affected 17 patients, or 4.1 percent, or because of patient preference, cited by 26 patients, or 6.3 percent. The critical question has always been whether lowering the dose compromises efficacy. The answer from this cohort appears to be no. Among the 46 patients who reduced their dose, the researchers observed no cases of disease progression or death after the reduction occurred, over a median follow-up of 10.9 months from the first dose modification. While the follow-up window is relatively short and the subgroup modest in size, the signal is reassuring for the many patients who need to taper their dose to manage side effects.

The study also shed light on a growing phenomenon in leukemia care: switching between BTK inhibitors. Fifty-four patients in the cohort moved to zanubrutinib from another BTK inhibitor without any evidence of disease progression, meaning they switched for tolerability or convenience rather than treatment failure. Thirty-two of these patients made the move because of adverse events on their previous drug, 19 because of patient preference, and four for unknown reasons, with some reasons overlapping. The median duration of zanubrutinib treatment after the switch was 10.1 months among patients who switched due to side effects and 16.5 months among those who switched by preference. Most notably, progression-free survival had not been reached in either group at the time of analysis, indicating that patients who transition from an older BTK inhibitor to zanubrutinib for non-progressive reasons can continue to achieve durable disease control on the newer agent.

From a technical standpoint, the study’s design merits attention. The investigators conducted a retrospective, multicenter cohort analysis drawing on data from hospitals across China, including Peking University People’s Hospital, the First Affiliated Hospital of Nanjing Medical University, Nanfang Hospital, West China Hospital, and several others, with Peking University People’s Hospital serving as the central ethics committee. The primary endpoint was progression-free survival, the standard measure of how long patients live without their disease worsening, analyzed with confidence intervals to quantify uncertainty. The three-year PFS estimate of 91.6 percent for treatment-naive patients carried a 95 percent confidence interval of 83.8 to 95.8 percent, while the 83.2 percent estimate for later-line patients spanned 74.6 to 89.1 percent. These intervals, while wide in places due to the evolving follow-up time, place real-world outcomes squarely in the territory previously reported in registration trials, a consistency that strengthens confidence in the drug’s effectiveness.

The distinction between initial and later-line therapy matters enormously in chronic lymphocytic leukemia, an indolent malignancy that predominantly affects older adults and often follows a relapsing course over many years. Patients receiving zanubrutinib as initial therapy had not been exposed to prior BTK inhibition and typically had fewer accumulated resistance mechanisms. Those receiving it later had often been through chemoimmunotherapy or earlier targeted agents. The roughly eight-percentage-point gap in three-year progression-free survival between the two groups is consistent with the expected biology, yet the fact that later-line patients still achieved better than 83 percent freedom from progression at three years underscores how much the BTK inhibitor class has reshaped the prognosis of relapsed and refractory disease, which was historically one of the most difficult scenarios to manage.

Why does real-world evidence of this kind matter so much? Registration trials enroll selected patients, often excluding those with significant comorbidities, competing medications, or atypical disease features, and they monitor adherence intensively. Routine practice is different. Patients forget doses, stop drugs because they feel well, reduce doses on their own initiative, and switch therapies based on quality-of-life considerations that never appear in a case report form. By documenting that only 3.7 percent of patients discontinued zanubrutinib because of adverse events, and that dose reductions did not precipitate disease progression, this nationwide cohort provides the kind of pragmatic evidence that health systems, guideline committees, and prescribing physicians need when weighing treatment options for a disease that may require years of continuous oral therapy.

The findings also carry implications for how clinicians counsel patients about side effect management. Patient preference was the single most common reason for both dose reduction and discontinuation in this cohort, a reminder that shared decision-making is not a formality but a genuine determinant of treatment trajectories. Some patients in the study chose to reduce or stop their medication despite adequate tolerability, and the data suggest that, at least within the observed follow-up, such choices did not immediately translate into disease progression. That said, the authors and the broader hematology community would caution that longer observation is needed before dose attenuation can be considered fully equivalent to continuous full-dose therapy, particularly given the indolent nature of the disease and the possibility of late relapse.

Taken together, the study offers a comprehensive portrait of zanubrutinib as it is actually used: a drug with high selectivity for its target, low rates of discontinuation for toxicity, reassuring outcomes after dose modification, and strong progression-free survival in both first-line and later-line settings. As BTK inhibitors continue to evolve and as fixed-duration combinations challenge the paradigm of continuous therapy, cohorts like this one, registered as NCT06489184 on ClinicalTrials.gov, will remain essential for understanding how these powerful targeted agents perform in the hands of real patients and real physicians, far from the protocolized confines of the clinical trial.

Subject of Research: Real-world effectiveness, dose modification and discontinuation patterns of the BTK inhibitor zanubrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma

Article Title: Dose modifications, discontinuation patterns and PFS of zanubrutinib in 410 CLL/SLL patients – a nationwide real-world cohort

Article References: Yang, S., Zhu, H., Hu, L., Feng, R., Guo, X., Niu, T., Shen, K., Li, Z., Dong, Y., Wang, B., Su, L., Wang, L., Wang, L., Sun, W., Fang, F., Zhao, Y., Huang, X., & Li, J. (2026). Dose modifications, discontinuation patterns and PFS of zanubrutinib in 410 CLL/SLL patients – a nationwide real-world cohort. BMC Cancer. https://doi.org/10.1186/s12885-026-17043-6

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17043-6

Keywords: zanubrutinib, chronic lymphocytic leukemia, small lymphocytic lymphoma, BTK inhibitor, progression-free survival, dose reduction, real-world evidence, drug discontinuation, adverse events, hematology, targeted therapy, BMC Cancer

The name MANTRA stands for Multi-view ANalysis with Tensor and matRix Alignment, and the framework was developed by Kevin De Azevedo, Yusuf Berk Oruc, and Florian Buettner, who contributed to the German Cancer Consortium and the Frankfurt Cancer Institute. Conceptually, MANTRA can be understood as a generalization of group factor analysis to tensor-valued data, or conversely, as an extension of classical tensor decomposition into the multi-view setting. It takes as input a collection of datasets, some three-dimensional and some two-dimensional, and decomposes them jointly into shared low-dimensional latent factors. Each mode of the data, whether patients, drugs, cytokines, cell types, or genes, receives its own embedding matrix, and products of these matrices yield interpretable loadings that expose interactions between the different dimensions.

What makes MANTRA technically distinctive is its Bayesian formulation with structured sparsity priors. The model places horseshoe priors on feature embeddings, a multi-scale shrinkage approach well suited to variational inference. Within this scheme, an Automatic Relevance Determination prior allows individual factors to be active in only a subset of data views, while local regularization encourages sparsity within each factor itself. This design has two practical consequences. First, unneeded factors are automatically driven toward zero, making the model remarkably robust when the true rank of the data is unknown, a common and frustrating problem in real applications. Second, the sparse factors highlight only the most relevant features, making the results biologically interpretable rather than opaque. Missing values, a perennial headache in clinical studies where not every omics layer can be profiled for every patient, are handled natively and in a principled manner.

The team validated MANTRA extensively on synthetic data before turning to real biology. In systematic benchmarks against PARAFAC, a state-of-the-art tensor decomposition implementation from the TensorLy package, MANTRA performed comparably in the high signal-to-noise regime and substantially better in the noisy, sparse, low-sample conditions that mimic real-world datasets. When the models were deliberately fitted with more factors than the true rank, MANTRA’s sparsity priors switched off the excess factors, whereas PARAFAC degraded. Scalability analyses on GPU hardware showed favorable scaling across sample counts, feature dimensions, and ranks, and sensitivity analyses confirmed that the choice of prior hyperparameters for the noise model leaves reconstruction accuracy stable across a broad range of data conditions.

The first real-world application focused on Chronic Lymphocytic Leukemia, a disease in which inter-patient heterogeneity strongly influences treatment outcomes. The researchers analyzed a published dataset of 192 primary CLL samples in which cell viability had been measured in response to 12 drugs under 17 different microenvironmental stimuli, complemented by bulk RNA sequencing of the same patients. This produced exactly the kind of mixed-order collection MANTRA was designed for: a third-order drug viability tensor of patients, drugs, and cytokines, alongside a second-order RNA-seq matrix of patients and genes. When trained on the drug tensor alone, MANTRA’s patient embeddings showed only a partial association with IGHV mutation status, one of the most important prognostic markers in CLL, distinguishing patients with typically aggressive unmutated disease from those with more indolent mutated disease.

The picture changed dramatically when the transcriptomic view was added. In the joint multi-view model, the patient embeddings separated sharply by IGHV status, and the drug loadings recovered known biological relationships, with drugs targeting the B-cell receptor, MAPK, and DNA damage response pathways clustering together. Quantitatively, the researchers used Leiden clustering of the learned latent space and measured alignment with clinical labels using adjusted Rand index and normalized mutual information, following standard practice from the single-cell integration literature. MANTRA outperformed MOFA+ and MOFA-FLEX, two leading matrix-based multi-omics tools, which had to flatten the three-dimensional drug tensor into stacks of two-dimensional matrices. MANTRA also separated patients by Trisomy 12, an intermediate-risk cytogenetic abnormality present in roughly ten to twenty percent of CLL patients, more accurately than the baselines, demonstrating that the model captures clinically meaningful axes of variation relevant to stratification and treatment response.

The second application pushed MANTRA into the single-cell arena, where the stakes were even higher. The team analyzed a multi-omics dataset from 18 pediatric patients with KMT2A-rearranged Acute Lymphoblastic Leukemia and 5 healthy donors, constructing two third-order tensors of patients, cell types, and features: one for single-cell RNA sequencing and one for single-cell ATAC sequencing. Because MANTRA tolerates missing values, it could use all 18 patients, whereas the specialized tool scITD, which requires every cell type to be observed in every donor, had to discard 7 of them. Both methods separated healthy donors from leukemia patients, but only MANTRA went further, splitting the patients into two distinct subgroups driven by a factor that was predominantly active in plasmacytoid dendritic cells, a rare immune cell population that turned out to be the surprising driver of disease heterogeneity.

Pathway analysis revealed what this plasmacytoid dendritic cell factor meant biologically. Genes loading strongly on the factor were enriched for interferon signaling and other immune-active pathways as well as endoplasmic reticulum stress programs, while lymphoid transcription factors such as ETV6 showed low loadings and genes typically implicated in T-cell lineage leukemia, including BCL2, MYC, and LYL1, showed high loadings. One patient subgroup carried a high-immune-activity, low-ER-stress program in their plasmacytoid dendritic cells, while the other occupied the opposite end of the spectrum. Critically, neither MOFA+, MOFA-FLEX, nor scITD detected this cell-type-specific stratification; all of their factors were dominated by blast cells. The finding was validated in an independent cohort of 7 pediatric B-ALL patients and 4 healthy donors, and when MANTRA was run on pediatric T-ALL data as a negative control, no such factor appeared, confirming that the plasmacytoid dendritic cell program is specific to B-cell acute lymphoblastic leukemia.

The linear structure of MANTRA is both its strength and its acknowledged limitation. Linear factor models are inherently interpretable, allowing biologists to trace each factor back to specific cell types, drugs, and pathways through the generalized loadings matrix. But capturing non-linear relationships would require kernel methods or deep architectures that would sacrifice precisely this transparency. The authors also note that in datasets where structural dependencies between dimensions are negligible, or where extreme sparsity and noise prevail, simpler matrix factorizations may remain equally effective or more stable. Identifiability and rotational invariance, perennial issues for all latent variable models, also apply here. Still, the researchers point toward supervised extensions of the framework as a promising future direction, albeit one that brings new overfitting challenges.

The implications reach well beyond leukemia. Drug screens that measure patient-derived cells across drugs and microenvironmental conditions, single-cell atlases that profile multiple tissues per donor, and multi-modal studies combining expression with chromatin accessibility all generate data with exactly the mixed-order tensor structure that MANTRA handles natively. By refusing to flatten higher-order structure into matrices, and by handling missing data through principled Bayesian inference rather than ad hoc imputation, the tool opens a window onto biological variation that existing methods systematically miss. The code is publicly available on GitHub, implemented in Python using the probabilistic programming library Pyro, and the discovery that a rare immune cell type defines clinically relevant leukemia subgroups offers a vivid demonstration of what becomes visible when algorithms finally learn to see data in all of its dimensions.

Subject of Research: Interpretable Bayesian integration of mixed-order multi-omics tensors for leukemia patient stratification

Article Title: Interpretable multi-omics integration across mixed-order tensors with MANTRA

Article References: De Azevedo, K., Oruc, Y. B., & Buettner, F. (2026). Interpretable multi-omics integration across mixed-order tensors with MANTRA. Molecular Systems Biology, 22(9), 1415-1429. https://doi.org/10.1038/s44320-026-00223-8

Image Credits: AI Generated

DOI: 10.1038/s44320-026-00223-8

Keywords: MANTRA, tensor decomposition, multi-omics, Bayesian inference, chronic lymphocytic leukemia, acute lymphoblastic leukemia, drug response, single-cell RNA-seq, single-cell ATAC-seq, plasmacytoid dendritic cells, structured sparsity, patient stratification